Sugi Predict

Sugi Predict / Compounds / SCHEMBL361389

SCHEMBL361389

SCHEMBL361389

CNc1cccc(C#N)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ MEN1 O00255 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ IDO1 P14902 1/20 0.51
▸ KCNA5 P22460 1/20 0.50
▸ PDK1 Q15118 1/20 0.47
▸ PDK2 Q15119 1/20 0.47
▸ PDK3 Q15120 1/20 0.47
▸ PDK4 Q16654 1/20 0.47
▸ HTT P42858 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ GRM4 Q14833 1/20 0.45
▸ ABCG2 Q9UNQ0 2/20 0.44
▸ ADORA2A P29274 1/20 0.44
▸ ADORA2B P29275 1/20 0.44
▸ ADORA1 P30542 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27475007 0.98 MAPT (0.51) MAPTALDH1A1MEN1KMT2AIDO1
SCHEMBL18630198 0.83 MAPT (0.50) MAPTALDH1A1MEN1KMT2AIDO1
SCHEMBL953597 0.82 ALDH1A1 (0.56) MAPTALDH1A1MEN1KMT2AIDO1
SCHEMBL17683703 0.79 ADORA2A (0.49) ALDH1A1MEN1KMT2AADORA2AADORA2B
SCHEMBL16375394 0.79 SYK (0.48) MAPTALDH1A1MEN1KMT2AABCG2
SCHEMBL95531 0.78 TSHR (0.42) MAPTALDH1A1MEN1KMT2AIDO1
SCHEMBL30460228 0.78 EGFR (0.43) MAPTALDH1A1MEN1KMT2AIDO1
SCHEMBL2892636 0.78 EGFR (0.43) MAPTALDH1A1MEN1KMT2AIDO1
SCHEMBL25062056 0.78 MAPT (0.53) MAPTALDH1A1MEN1KMT2AIDO1
SCHEMBL14042535 0.78 MAPT (0.58) MAPTALDH1A1MEN1KMT2AIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110669058-A Tricyclic quinolone carboxylic acid and preparation method thereof 江西农业大学 2020-01-10 — — CN claimed
CN-108698992-A 2- cyano isoindoline derivatives for treating cancer 特殊治疗有限公司 2018-10-23 — — CN claimed
EP-2593425-B1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE AGIOS PHARMACEUTICALS INC (US) 2018-10-17 — — EP claimed
EP-3030554-B1 PIPERIDINE UREA DERIVATIVES MERCK PATENT GMBH (DE) 2018-02-28 — — EP claimed
US-20160264621-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC (US) 2016-09-15 — — US claimed
EP-3030554-A1 PIPERIDINE UREA DERIVATIVES Merck Patent GmbH (DE) 2016-06-15 — — EP claimed
WO-2015018475-A1 PIPERIDINE UREA DERIVATIVES MERCK PATENT GMBH (DE) 2015-02-12 — — WO claimed
US-20130184222-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC (US) 2013-07-18 — — US claimed
EP-2593425-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE Agios Pharmaceuticals, Inc. (US) 2013-05-22 — — EP claimed
WO-2012009678-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE AGIOS PHARMACEUTICALS, INC. (US) 2012-01-19 — — WO claimed
EP-4370207-B1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES INC (US) 2025-12-17 — — EP disclosed
EP-4608816-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF Monte Rosa Therapeutics AG (CH) 2025-09-03 — — EP disclosed
US-20250263395-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2025-08-21 — — US disclosed
US-20240368137-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES, INC. 2024-11-07 — — US disclosed
US-12012398-B2 Bicyclic compounds as androgen receptor modulators NIDO BIOSCIENCES, INC. (US) 2024-06-18 — — US disclosed
US-5276148-A Phenylazobenzenes or naphthylazobenzenes having a plurality of fiber-reactive groups BASF AKTIENGESELLSCHAFT (DE) 1994-01-04 — — US disclosed
US-5214207-A Intermediates for reactive dyes BASF AKTIENGESELLSCHAFT (DE) 1993-05-25 — — US disclosed
EP-0515844-A1 Phenylazo- or naphthylazobenzenes with several reactive groups BASF Aktiengesellschaft (DE) 1992-12-02 — — EP disclosed
US-5091516-A PHENYL- OR NAPHTHYLAZOBENZENES WITH MULTIPLE REACTIVE GROUPS AND INTERMEDIATES THEREFOR BASF AKTIENGESELLSCHAFT (DE) 1992-02-25 — — US disclosed
EP-0437699-A1 Phenylazo- or naphthylazobenzene with several reactive groups as well as their intermediate products BASF Aktiengesellschaft (DE) 1991-07-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184222-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE IDH1, IDH3B, IDH3A MAPT 2881/4885ALDH1A1 597/4885MEN1 719/4885
US-20240368137-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 MAPT 1341/4885ALDH1A1 2558/4885MEN1 4123/4885
US-12012398-B2 Bicyclic compounds as androgen receptor modulators AR, FSHR, NCOA3 MAPT 1385/4885ALDH1A1 2865/4885MEN1 4034/4885
US-20250263395-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF CDK2, SKP2, CDK1 MAPT 3248/4885ALDH1A1 3818/4885MEN1 2754/4885
US-20160264621-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE IDH1, IDH3B, IDH3A MAPT 2881/4885ALDH1A1 597/4885MEN1 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.